| Name | Title | Contact Details |
|---|
We`re the only on-demand healthcare concierge for employers, health plans and health systems. Join our customers who experience industry-leading engagement levels, satisfaction scores unseen in health care, better health outcomes, and substantial medical cost savings of more than 10 percent. Our team of compassionate, trusted professionals, supported by breakthrough science and technologies guide consumers through the healthcare system in a deeply personalized manner. We`ve been recognized as one of the nation`s 25 most promising companies by Forbes magazine, the fastest-growing private healthcare company by Inc. 500, and a top workplace by multiple news publications.
Care Rx Corporate Office is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GroupOne Services is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Igentify® is a digital health company. We help clinicians, laboratories, and patients access, interpret, and use genetic information and education more effectively. Igentify developed the world`s first Digital Genetic Assistant, a software-based decision support platform. Our platform is capable of providing a fully scalable end-to-end genetic counseling solution in both clinical as well as non-clinical (direct-to-consumer) genetic testing set up. The platform is built for various genotyping technologies like microarray and next-generation sequencing (NGS). It can be customized to a broad spectrum of genetic and genomic tests offered by the test providers. Founded in Oct. 2016, Igentify`s team of globally renowned geneticists, highly experienced software developers, creative animators, and UX/UI designers, is redefining the protocols of traditional medicine. In Jan. 2019, Deloitte selected Igentify as one of the Israeli startups at the forefront of the Digital R&D Revolution.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.